Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life. Patients, dental professionals and medical oncologists will benefit from a greater understanding of the best oral care follow up practices of breast cancer survivors using aromatase inhibitors.
Quality of Life
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Oral Health in Breast Cancer Survivors on Aromatase Inhibitors|
- Periodontal diseases [ Time Frame: At the time of study visit ] [ Designated as safety issue: No ]
- Alveolar bone loss using salivary and serum-derived bone markers. [ Time Frame: At the time of study visit ] [ Designated as safety issue: No ]
- Oral Health Related Quality of Life (OHRQoL) assessed via questionnaire [ Time Frame: At the time of study visit ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Each patient will have 5ml of blood collected at the visit. Saliva, and urine will also be collected at the study visit.
|Study Start Date:||April 2012|
|Study Completion Date:||March 2015|
|Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
This cross-sectional prevalence study seeks to investigate the incidence and severity of oral health changes, specifically of periodontal conditions, among breast cancer survivors and the ways in which these outcomes affect their quality of life.
- To determine the prevalence and severity of oral conditions in postmenopausal women with early stage breast cancer using adjuvant AI therapy as compared to postmenopausal women not using adjuvant AI therapy.
- To determine if adjuvant AI therapy use is associated with greater alveolar bone loss or increased levels of bone turnover biomarkers in postmenopausal women with cancer undergoing adjuvant AI therapy compared to postmenopausal women not receiving AI therapy.
- To determine the oral health-related quality of life among postmenopausal women with early stage breast cancer who are receiving adjuvant AI therapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01693731
|United States, Michigan|
|Michigan Center For Oral Health Research (MCOHR)|
|Ann Arbor, Michigan, United States, 48106|
|Principal Investigator:||L. Susan Taichman, RDH MPH PhD||University of Michigan|